AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.

臺大醫院-腫瘤醫學部;臺大醫學院-腫瘤醫學研究所;臺大醫學院-癌症研究中心;Kim, Dong-WanDong-WanKimYang, James Chih-HsinJames Chih-HsinYangChen, KanKanChenCheng, ZiqiangZiqiangChengYin, LucyLucyYinMartin, Paul DavidPaul DavidMartinYang, ZhenfanZhenfanYangJiang, HaiyiHaiyiJiangAhn, Myung-JuMyung-JuAhn2017-06-272018-07-092017-06-272018-07-092015http://ntur.lib.ntu.edu.tw//handle/246246/280105[SDGs]SDG3AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.